Open Peer Review on Qeios

Technetium Tc 99m-3PRGD2

National Cancer Institute

Source

National Cancer Institute. <u>Technetium Tc 99m-3PRGD2</u>. NCI Thesaurus. Code C104007.

A radiopharmaceutical agent comprised of a pegylated arginine-glycine-aspartic acid (RGD) dimer (PRGD2) labeled with technetium T c 99m, with potential alphaVbeta3 integrin imaging activity when used with single photon emission computed tomography (SPECT). After intravenous administration of technetium T c 99m-3PRGD2, the RGD moiety binds to alphaVbeta3 integrin on the cell membrane via the cyclic RGD motif. Upon PET imaging, alphaVbeta3 integrin-expressing tumor cells can be visualized and expression levels can be quantified. Compared to other radiolabeled RGD-containing peptides, this agent shows an increased affinity for alphaVbeta3 integrin, enhanced tumor uptake as well as improved pharmacokinetics. AlphaVbeta3 integrin, a member of the integrin receptor family, is overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells; this receptor plays a key role in angiogenesis, tumor proliferation and survival.